DOCSLIB.ORG

FHL3 Differentially Regulates the Expression of Myhc Isoforms Through Interactions with Myod and Pcreb

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FHL3 Differentially Regulates the Expression of Myhc Isoforms Through Interactions with Myod and Pcreb Cellular Signalling 28 (2016) 60–73 Contents lists available at ScienceDirect Cellular Signalling journal homepage: www.elsevier.com/locate/cellsig FHL3 differentially regulates the expression of MyHC isoforms through interactions with MyoD and pCREB Yunxia Zhang, Wentao Li, Mingfei Zhu, Yuan Li, Zaiyan Xu ⁎,BoZuo⁎ Key Laboratory of Swine Genetics and Breeding, Ministry of Agriculture and Key Lab of Agricultural Animal Genetics and Breeding, Ministry of Education, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, PR China article info abstract Article history: In skeletal muscle, muscle fiber types are defined by four adult myosin heavy chain (MyHC) isoforms. Four Received 10 June 2015 and a half LIM domain protein 3 (FHL3) regulates myoblasts differentiation and gene expression by acting Received in revised form 9 October 2015 as a transcriptional co-activator or co-repressor. However, how FHL3 regulates MyHC expression is currently Accepted 19 October 2015 not clear. In this study, we found that FHL3 down-regulated the expression of MyHC 1/slow and up-regulated Available online 22 October 2015 the expression of MyHC 2a and MyHC 2b, whereas no significant effect was found on MyHC 2x expression. Keywords: MyoD and phosphorylated cAMP response element binding protein (pCREB) played important roles in Muscle fiber type the regulation of MyHC 1/slow and MyHC 2a expression by FHL3, respectively. FHL3 could interact with FHL3 MyoD, CREB and pCREB in vivo. pCREB had stronger interaction with the cyclic AMP-responsive elements MyoD (CRE) of the MyHC 2a promoter compared with CREB, and FHL3 significantly affected the binding capacity MyHC of pCREB to CRE. We established a model in which FHL3 promotes the expression of MyHC 2a through CREB- CREB mediated transcription and inhibits the expression of MyHC 1/slow by inhibiting MyoD transcription activity during myogenesis. Our data support the notion that FHL3 plays important roles in the regulation of muscle fiber type composition. © 2015 Elsevier Inc. All rights reserved. 1. Introduction larger in diameter. The high proportion of MyHC 2b contributes to an in- crease in muscle mass [5]. However, the overall proportion of MyHC 2b Skeletal muscle comprises different types of muscle fibers. Tradition- has been shown to correlate with the occurrence of pig PSE (pale, soft ally, fiber types are classified as slow-oxidative (1 type), fast oxidative- and exudative) meat, which could lead to a fast pH decline after glycolytic (2a type) and fast-glycolytic (2b type) fibers, according to slaughter [6,7]. In human beings, fast-dominant skeletal muscle their contraction and metabolic characteristics [1]. Fiber types are con- induced by denervation easily leads to skeletal muscle atrophy com- vertible in adult skeletal muscle in response to exercise training [2]. pared with type 1 fibers [8]. Oxidative enzymatic activities in human Four postnatal fiber types exist in skeletal muscle, each defined by the skeletal muscle are correlated with fiber type composition [9].The presence of dominant MyHC isoforms (MyHC 1/slow, MyHC 2a, MyHC fastest, most powerful muscle fiber type (type 2b fibers) tends to 2b, MyHC 2x) [3]. In animal production, meat quantity and quality are be lost in the elderly population [10,11], suggesting that the compo- significantly affected by the composition of the four MyHC isoforms [4]. sition of skeletal muscle is associated with aging-related loss of mus- Skeletal muscle with a higher composition of type 2b fibers tends to be cle function and muscle disease. To date, several signal transduction pathways, including myogenic regulatory transcription factors (MRFs), insulin-like growth factors (IGFs), calcineurin-nuclear factor of acti- Abbreviations: MyHC, myosin heavy chain; FHL, four and half LIM domain protein; vated T cells (CaN-NFAT), CCAAT enhancer binding protein δ (C/EBP-δ) CRE, cyclic AMP-responsive element; CREB, cAMP-response-element-binding protein; and peroxisome proliferator-activated receptor-γ coactivator (PGC)- PKA, cAMP-activited protein kinase A; MyoG, myogenin; MyoD, myogenic differentiation 1α,havebeenreportedinregulatingfiber type-specific gene expressions 1; SDS, Sodium Dodecyl Sulfate; cDNA, complementary DNA; siRNA, small hairpin RNA; – PCR, polymerase chain reaction; MRFs, myogenic regulatory transcription factors; IGFs, [12 15]. insulin-like growth factors; CaN-NFAT, calcineurin-nuclear factor of activated T cells; The LIM domain has one or more cysteine-rich zinc fingers and C/EBP-δ, CCAAT enhancer binding protein δ; PGC-1α, peroxisome proliferator-activated regulates gene transcription [16]. The LIM domain is a zinc-binding receptor-γ coactivator-1α; CDS, coding sequence; bp, base pair; PVD, polyvinylidene fluo- structural motif, of which the consensus amino acid sequence is ride; EMSA, Electrophoretic mobility shift assay; ChIP, chromatin immunoprecipitation. CX2CX16–23HX2CX2CX2CX16–21CX2-3 (C/H/D) [17]. The LIM domain ⁎ Corresponding authors. E-mail addresses: [email protected] (Z. Xu), [email protected] lacks DNA-binding ability and is involved in gene expression and cell (B. Zuo). differentiation through protein–protein interactions [16]. The four and http://dx.doi.org/10.1016/j.cellsig.2015.10.008 0898-6568/© 2015 Elsevier Inc. All rights reserved. Y. Zhang et al. / Cellular Signalling 28 (2016) 60–73 61 a half LIM domain (FHL) proteins, including FHL1, FHL2, FHL3, FHL4 listed in Table 1. The mutants of CREB binding sites were generated and ACT, are a family of LIM-only proteins with four-and-a-half LIM using the overlapping extension PCR and mutagenic primers. domains and can act as transcriptional coactivators [18]. Fhl3 is high- ly expressed in skeletal muscle [18-20] and interacts with other pro- 2.2. Cell culture and differentiation of C2C12 myoblasts teins, including FHL2, CREB, Sox15, MZF-1, BKLF, Ang and MT-1X, as a transcriptional co-activator or co-repressor [18,21–26].FHL3has Mouse C2C12 (ATCC) myoblasts were cultured in 10% (v/v)fetal been reported to play important roles in cell growth, development, bovine serum (Gibco, Australia) in DMEM (high-glucose Dulbecco's tumorigenesis and cancer [27–30].Inskeletalmuscle,FHL3 modified Eagle's medium) (Hyclone, USA) under humidified air con- localizes to the nucleus and focal adhesions and is a significant regu- taining 5% CO2 at 37 °C, and were differentiated at confluence in lator of actin cytoskeletal dynamics in skeletal muscle [31].FHL3 DMEM with 2% horse serum (Gibco, USA). contributes to the regulation of MyoD dependent transcription of muscle specific genes during myogenesis [32]. In pig production, a 2.3. Transfection of plasmid DNA or siRNA oligonucleotides polymorphism within the coding region of pig Fhl3 is also signifi- cantly associated with meat mass and quality traits [19,20].Based Transfections were performed using plasmid (4 μg) or siRNA on these results, we speculat that FHL3 may regulate the expression (100 pmol) by Lipofectamine 2000 (9 μl) (Invitrogen, USA) after of MyHC isoforms of different muscle fiber types, thereby regulating seeded C2C12 myoblasts had been allowed to settle for 12–18 h, the fiber type composition of skeletal muscle. However, no studies according to the manufacturer's instruction. Fhl3 small hairpin RNA regarding the regulation of MyHC gene expression by FHL3 have (siRNA) oligonucleotides were synthesized according to Mm_FHL3_2_HP been reported thus far. In this study, we present a novel molecular siRNA (SI01002890, Qiagen, Germany) and transfected into C2C12 mechanism for the regulation of MyHC expression by FHL3, which myoblasts as previously described [32]. Creb siRNA oligonucleotides may contribute to meat quality control and may benefitmuscledisease (S: GGACCUUUACUGCCACAAATT; A: UUUGUGGCAGUAAAGGUCCTT) therapy in the future. and MyoD siRNA oligonucleotides (S: CCCCAAUGCGAUUUAUCATT; A: UGAUAAAUCGCAUUGGGGTT) were designed and synthesized by 2. Material and methods GenePharma (China, Shanghai). 2.1. Plasmid constructs 2.4. Quantitative real-time PCR The coding sequence (CDS) of the Fhl3 gene (870 bp) was obtained Total RNA from C2C12 myoblasts was extracted using TRIzol reagent by polymerase chain reaction (PCR) using cDNA (complementary (Invitrogen, USA). The concentration and quality of RNA were assessed DNA) of C2C12 myoblasts as a template. The 5′ and 3′ ends of the with a NanoDrop 2000 (Thermo, USA) and agarose gel electrophoresis. primers contain BamH IorXba Ienzymesites(Table 1). The ampli- One microgram of total RNA was used for reverse transcription with the fied CDS was digested with BamH IandXba I and was then ligated PrimeScript RTreagent kit with gDNA Eraser (Takara, Japan). The quan- into pcDNA3.1 using T4 DNA Ligase (Takara, Japan) to generate titative real-time PCR reaction was performed in a LightCycler 480 II pcDNA3.1-FHL3. (Roche, Switzerland) system using the THUNDERBIRD™ probe qPCR The CDS of Creb (1026 bp) was obtained by PCR using cDNA of Mix or SYBR®Green Real-time PCR Master Mix (Toyobo, Japan). The C2C12 myoblasts as a template. The 5′ and 3′ ends of the primers sequence of TaqMan probes and primers can be found in Table 2 and ΔΔ contain Kpn IorXho I enzyme sites (Table 1). The amplified CDS was were determined according to the literature [33].TheCt(2- Ct) digested with Kpn IandXho I and was then ligated into pcDNA3.1 method was used to analyze the relative gene expression data according using T4 DNA Ligase to generate pcDNA3.1-CREB. to the literature [34]. Five deletion fragments of the
Load more

Recommended publications
  • FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating Tgfβ/Smad-Independent Pathways in Gastric Cancer
    FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating TGFβ/Smad-Independent Pathways in Gastric Cancer Guodong Cao First Aliated Hospital of Anhui Medical University Pengping Li Hangzhou Xiaoshan No 1 People's Hospital Qiang Sun Xuzhou Medical University Sihan Chen First Aliated Hospital of Anhui Medical University Xin Xu First Aliated Hospital of Anhui Medical University Xiaobo He First Aliated Hospital of Anhui Medical University Zhenyu Wang Hangzhou Xiaoshan No 1 People's Hospital Peng Chen First Aliated Hospital of Anhui Medical University Maoming Xiong ( [email protected] ) First Aliated Hospital of Anhui Medical University Bo Chen First Aliated Hospital of Anhui Medical University Research Keywords: EMT, Chemotherapy resistance, FHL3, Ubiquitination, Gastric cancer Posted Date: October 9th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-87249/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. ReLoaadd iFngu l[Ml LaitchJeanxs]/ejax/output/CommonHTML/jax.js Page 1/28 Loading [MathJax]/jax/output/CommonHTML/jax.js Page 2/28 Abstract Background: Gastric cancer presents high risk of metastasis and chemotherapy resistance. Hence, the mechanistic understanding of the tumor metastasis and chemotherapy resistance is quietly important. Methods: TCGA database and clinical samples are used for exploring the role of FHL3 in disease progression and prognosis. The roles of FHL3 in metastasis and chemotherapy resistance are explored in vitro and in vivo by siRNA or shRNA treatment. Finally, we explore the FHL3-mediated EMT and chemotherapy resistance. Results: mRNA and protein level of FHL3 is signicantly up-regulated in gastric cancer tissues when compares with it in adjacent tissue.
    [Show full text]
  • In Vivo Studies Using the Classical Mouse Diversity Panel
    The Mouse Diversity Panel Predicts Clinical Drug Toxicity Risk Where Classical Models Fail Alison Harrill, Ph.D The Hamner-UNC Institute for Drug Safety Sciences 0 The Importance of Predicting Clinical Adverse Drug Reactions (ADR) Figure: Cath O’Driscoll Nature Publishing 2004 Risk ID PGx Testing 1 People Respond Differently to Drugs Pharmacogenetic Markers Identified by Genome-Wide Association Drug Adverse Drug Risk Allele Reaction (ADR) Abacavir Hypersensitivity HLA-B*5701 Flucloxacillin Hepatotoxicity Allopurinol Cutaneous ADR HLA-B*5801 Carbamazepine Stevens-Johnson HLA-B*1502 Syndrome Augmentin Hepatotoxicity DRB1*1501 Ximelagatran Hepatotoxicity DRB1*0701 Ticlopidine Hepatotoxicity HLA-A*3303 Average preclinical populations and human hepatocytes lack the diversity to detect incidence of adverse events that occur only in 1/10,000 people. Current Rodent Models of Risk Assessment The Challenge “At a time of extraordinary scientific progress, methods have hardly changed in several decades ([FDA] 2004)… Toxicologists face a major challenge in the twenty-first century. They need to embrace the new “omics” techniques and ensure that they are using the most appropriate animals if their discipline is to become a more effective tool in drug development.” -Dr. Michael Festing Quantitative geneticist Toxicol Pathol. 2010;38(5):681-90 Rodent Models as a Strategy for Hazard Characterization and Pharmacogenetics Genetically defined rodent models may provide ability to: 1. Improve preclinical prediction of drugs that carry a human safety risk 2.
    [Show full text]
  • Bioinformatic Analysis of Structure and Function of LIM Domains of Human Zyxin Family Proteins
    International Journal of Molecular Sciences Article Bioinformatic Analysis of Structure and Function of LIM Domains of Human Zyxin Family Proteins M. Quadir Siddiqui 1,† , Maulik D. Badmalia 1,† and Trushar R. Patel 1,2,3,* 1 Alberta RNA Research and Training Institute, Department of Chemistry and Biochemistry, University of Lethbridge, 4401 University Drive, Lethbridge, AB T1K 3M4, Canada; [email protected] (M.Q.S.); [email protected] (M.D.B.) 2 Department of Microbiology, Immunology and Infectious Disease, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive, Calgary, AB T2N 4N1, Canada 3 Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada * Correspondence: [email protected] † These authors contributed equally to the work. Abstract: Members of the human Zyxin family are LIM domain-containing proteins that perform critical cellular functions and are indispensable for cellular integrity. Despite their importance, not much is known about their structure, functions, interactions and dynamics. To provide insights into these, we used a set of in-silico tools and databases and analyzed their amino acid sequence, phylogeny, post-translational modifications, structure-dynamics, molecular interactions, and func- tions. Our analysis revealed that zyxin members are ohnologs. Presence of a conserved nuclear export signal composed of LxxLxL/LxxxLxL consensus sequence, as well as a possible nuclear localization signal, suggesting that Zyxin family members may have nuclear and cytoplasmic roles. The molecular modeling and structural analysis indicated that Zyxin family LIM domains share Citation: Siddiqui, M.Q.; Badmalia, similarities with transcriptional regulators and have positively charged electrostatic patches, which M.D.; Patel, T.R.
    [Show full text]
  • Mouse Population-Guided Resequencing Reveals That Variants in CD44 Contribute to Acetaminophen-Induced Liver Injury in Humans
    Downloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Letter Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans Alison H. Harrill,1,2,12 Paul B. Watkins,3,12 Stephen Su,6 Pamela K. Ross,2 David E. Harbourt,5 Ioannis M. Stylianou,7 Gary A. Boorman,8 Mark W. Russo,3 Richard S. Sackler,9 Stephen C. Harris,11 Philip C. Smith,5 Raymond Tennant,8 Molly Bogue,7 Kenneth Paigen,7 Christopher Harris,9,10 Tanupriya Contractor,9 Timothy Wiltshire,5 Ivan Rusyn,1,2,14 and David W. Threadgill1,4,13,14,15 1Curriculum in Toxicology, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 2Department of Environmental Sciences and Engineering, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 3Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 4Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 5School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 6Department of Mouse Genetics, Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA; 7The Jackson Laboratory, Bar Harbor, Maine 04609, USA; 8National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA; 9Verto Institute Research Laboratories, New Brunswick, New Jersey 08903, USA; 10Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA; 11Purdue Pharma L.P., Stamford, Connecticut 06901, USA; 12Hamner-UNC Center for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709, USA; 13Department of Genetics, North Carolina State University, Raleigh, North Carolina 27695, USA Interindividual variability in response to chemicals and drugs is a common regulatory concern.
    [Show full text]
  • Functional Genomics Atlas of Synovial Fibroblasts Defining Rheumatoid Arthritis
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248230; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability Xiangyu Ge1*, Mojca Frank-Bertoncelj2*, Kerstin Klein2, Amanda Mcgovern1, Tadeja Kuret2,3, Miranda Houtman2, Blaž Burja2,3, Raphael Micheroli2, Miriam Marks4, Andrew Filer5,6, Christopher D. Buckley5,6,7, Gisela Orozco1, Oliver Distler2, Andrew P Morris1, Paul Martin1, Stephen Eyre1* & Caroline Ospelt2*,# 1Versus Arthritis Centre for Genetics and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK 2Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland 3Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia 4Schulthess Klinik, Zurich, Switzerland 5Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK 6NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK 7Kennedy Institute of Rheumatology, University of Oxford Roosevelt Drive Headington Oxford UK *These authors contributed equally #corresponding author: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248230; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Chain Gene Induced by GM-CSF Β Receptor Regulation of Human High-Affinity Ige Molecular Mechanisms for Transcriptional
    Molecular Mechanisms for Transcriptional Regulation of Human High-Affinity IgE Receptor β-Chain Gene Induced by GM-CSF This information is current as Kyoko Takahashi, Natsuko Hayashi, Shuichi Kaminogawa of September 23, 2021. and Chisei Ra J Immunol 2006; 177:4605-4611; ; doi: 10.4049/jimmunol.177.7.4605 http://www.jimmunol.org/content/177/7/4605 Downloaded from References This article cites 39 articles, 16 of which you can access for free at: http://www.jimmunol.org/content/177/7/4605.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 23, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Molecular Mechanisms for Transcriptional Regulation of Human High-Affinity IgE Receptor ␤-Chain Gene Induced by GM-CSF1 Kyoko Takahashi,*† Natsuko Hayashi,*‡ Shuichi Kaminogawa,† and Chisei Ra2* The ␤-chain of the high-affinity receptor for IgE (Fc␧RI) plays an important role in regulating activation of Fc␧RI-expressing cells such as mast cells in allergic reactions.
    [Show full text]
  • Pig Antibodies
    Pig Antibodies gene_name sku Entry_Name Protein_Names Organism Length Identity CDX‐2 ARP31476_P050 D0V4H7_PIG Caudal type homeobox 2 (Fragment) Sus scrofa (Pig) 147 100.00% CDX‐2 ARP31476_P050 A7MAE3_PIG Caudal type homeobox transcription factor 2 (Fragment) Sus scrofa (Pig) 75 100.00% Tnnt3 ARP51286_P050 Q75NH3_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 271 85.00% Tnnt3 ARP51286_P050 Q75NH2_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 266 85.00% Tnnt3 ARP51286_P050 Q75NH1_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 260 85.00% Tnnt3 ARP51286_P050 Q75NH0_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 250 85.00% Tnnt3 ARP51286_P050 Q75NG8_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 266 85.00% Tnnt3 ARP51286_P050 Q75NG7_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 260 85.00% Tnnt3 ARP51286_P050 Q75NG6_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 250 85.00% Tnnt3 ARP51286_P050 TNNT3_PIG Troponin T, fast skeletal muscle (TnTf) Sus scrofa (Pig) 271 85.00% ORF Names:PANDA_000462 EMBL EFB13877.1OrganismAiluropod High mobility group protein B2 (High mobility group protein a melanoleuca (Giant panda) ARP31939_P050 HMGB2_PIG 2) (HMG‐2) Sus scrofa (Pig) 210 100.00% Agpat5 ARP47429_P050 B8XTR3_PIG 1‐acylglycerol‐3‐phosphate O‐acyltransferase 5 Sus scrofa (Pig) 365 85.00% irf9 ARP31200_P050 Q29390_PIG Transcriptional regulator ISGF3 gamma subunit (Fragment) Sus scrofa (Pig) 57 100.00% irf9 ARP31200_P050 Q0GFA1_PIG Interferon regulatory factor 9 Sus scrofa (Pig)
    [Show full text]
  • The Viral Oncoproteins Tax and HBZ Reprogram the Cellular Mrna Splicing Landscape
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427104; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The viral oncoproteins Tax and HBZ reprogram the cellular mRNA splicing landscape Charlotte Vandermeulen1,2,3, Tina O’Grady3, Bartimee Galvan3, Majid Cherkaoui1, Alice Desbuleux1,2,4,5, Georges Coppin1,2,4,5, Julien Olivet1,2,4,5, Lamya Ben Ameur6, Keisuke Kataoka7, Seishi Ogawa7, Marc Thiry8, Franck Mortreux6, Michael A. Calderwood2,4,5, David E. Hill2,4,5, Johan Van Weyenbergh9, Benoit Charloteaux2,4,5,10, Marc Vidal2,4*, Franck Dequiedt3*, and Jean-Claude Twizere1,2,11* 1Laboratory of Viral Interactomes, GIGA Institute, University of Liege, Liege, Belgium.2Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, MA, USA.3Laboratory of Gene Expression and Cancer, GIGA Institute, University of Liege, Liege, Belgium.4Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. 5Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.6Laboratory of Biology and Modeling of the Cell, CNRS UMR 5239, INSERM U1210, University of Lyon, Lyon, France.7Department of Pathology and Tumor Biology, Kyoto University, Japan.8Unit of Cell and Tissue Biology, GIGA Institute, University of Liege, Liege, Belgium.9Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, Catholic University of Leuven, Leuven, Belgium.10Department of Human Genetics, CHU of Liege, University of Liege, Liege, Belgium.11Lead Contact. *Correspondence: [email protected]; [email protected]; [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427104; this version posted January 18, 2021.
    [Show full text]
  • Discovery and Systematic Characterization of Risk Variants and Genes For
    medRxiv preprint doi: https://doi.org/10.1101/2021.05.24.21257377; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . 1 Discovery and systematic characterization of risk variants and genes for 2 coronary artery disease in over a million participants 3 4 Krishna G Aragam1,2,3,4*, Tao Jiang5*, Anuj Goel6,7*, Stavroula Kanoni8*, Brooke N Wolford9*, 5 Elle M Weeks4, Minxian Wang3,4, George Hindy10, Wei Zhou4,11,12,9, Christopher Grace6,7, 6 Carolina Roselli3, Nicholas A Marston13, Frederick K Kamanu13, Ida Surakka14, Loreto Muñoz 7 Venegas15,16, Paul Sherliker17, Satoshi Koyama18, Kazuyoshi Ishigaki19, Bjørn O Åsvold20,21,22, 8 Michael R Brown23, Ben Brumpton20,21, Paul S de Vries23, Olga Giannakopoulou8, Panagiota 9 Giardoglou24, Daniel F Gudbjartsson25,26, Ulrich Güldener27, Syed M. Ijlal Haider15, Anna 10 Helgadottir25, Maysson Ibrahim28, Adnan Kastrati27,29, Thorsten Kessler27,29, Ling Li27, Lijiang 11 Ma30,31, Thomas Meitinger32,33,29, Sören Mucha15, Matthias Munz15, Federico Murgia28, Jonas B 12 Nielsen34,20, Markus M Nöthen35, Shichao Pang27, Tobias Reinberger15, Gudmar Thorleifsson25, 13 Moritz von Scheidt27,29, Jacob K Ulirsch4,11,36, EPIC-CVD Consortium, Biobank Japan, David O 14 Arnar25,37,38, Deepak S Atri39,3, Noël P Burtt4, Maria C Costanzo4, Jason Flannick40, Rajat M 15 Gupta39,3,4, Kaoru Ito18, Dong-Keun Jang4,
    [Show full text]
  • Identifying the Risky SNP of Osteoporosis with ID3-PEP Decision Tree Algorithm
    Hindawi Complexity Volume 2017, Article ID 9194801, 8 pages https://doi.org/10.1155/2017/9194801 Research Article Identifying the Risky SNP of Osteoporosis with ID3-PEP Decision Tree Algorithm Jincai Yang,1 Huichao Gu,1 Xingpeng Jiang,1 Qingyang Huang,2 Xiaohua Hu,1 and Xianjun Shen1 1 School of Computer Science, Central China Normal University, Wuhan 430079, China 2School of Life Science, Central China Normal University, Wuhan 430079, China Correspondence should be addressed to Jincai Yang; [email protected] Received 31 March 2017; Revised 26 May 2017; Accepted 8 June 2017; Published 7 August 2017 Academic Editor: Fang-Xiang Wu Copyright © 2017 Jincai Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In the past 20 years, much progress has been made on the genetic analysis of osteoporosis. A number of genes and SNPs associated with osteoporosis have been found through GWAS method. In this paper, we intend to identify the suspected risky SNPs of osteoporosis with computational methods based on the known osteoporosis GWAS-associated SNPs. The process includes two steps. Firstly, we decided whether the genes associated with the suspected risky SNPs are associated with osteoporosis by using random walk algorithm on the PPI network of osteoporosis GWAS-associated genes and the genes associated with the suspected risky SNPs. In order to solve the overfitting problem in ID3 decision tree algorithm, we then classified the SNPs with positive results based on their features of position and function through a simplified classification decision tree which was constructed by ID3 decision tree algorithm with PEP (Pessimistic-Error Pruning).
    [Show full text]
  • Integrated Transcriptomic, Phenotypic, and Functional Study Reveals Tissue-Specific Immune Properties of Mesenchymal Stromal
    Integrated Transcriptomic, Phenotypic, and Functional Study Reveals Tissue-Specific Immune Properties of Mesenchymal Stromal Cells Cédric Ménard, Joelle Dulong, David Roulois, Benjamin Hebraud, Léa Verdière, Céline Pangault, Vonick Sibut, Isabelle Bezier, Nadège Bescher, Céline Monvoisin, et al. To cite this version: Cédric Ménard, Joelle Dulong, David Roulois, Benjamin Hebraud, Léa Verdière, et al.. Inte- grated Transcriptomic, Phenotypic, and Functional Study Reveals Tissue-Specific Immune Prop- erties of Mesenchymal Stromal Cells. STEM CELLS, AlphaMed Press, 2020, 38 (1), pp.146-159. 10.1002/stem.3077. hal-02282131 HAL Id: hal-02282131 https://hal-univ-rennes1.archives-ouvertes.fr/hal-02282131 Submitted on 10 Sep 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Stem Cells Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells Journal: Stem Cells Manuscript ID Draft Wiley - Manuscript Type: Original Research Date Submitted by Forthe Peer Review n/a Author: Complete
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,671,085 B2 Downes Et Al
    USOO7671085B2 (12) United States Patent (10) Patent No.: US 7,671,085 B2 DOWnes et al. (45) Date of Patent: Mar. 2, 2010 (54) NON-STEROIDAL FARNESOIDX RECEPTOR 4,265,874 A 5/1981 Bonsen et al. MODULATORS AND METHODS FOR THE 5,151,442 A 9, 1992 Garcia et al. USE THEREOF FOREIGN PATENT DOCUMENTS (75) Inventors: Michael R. Downes, San Diego, CA WO WOOO/37077 6, 2000 (US); Ronald M. Evans, La Jolla, CA WO WOOOf 76.523 12/2000 (US) WO WO 2004/046.162 6, 2004 OTHER PUBLICATIONS (73) Assignee: The Salk Institute for Biological Fi1Orucci iS. S, RizzoRIZZO (J,G. DoniniJonini A,A. DistruttiJS 1 E.E, and SanlucciSantucci L.L, “Targetilargeting Studies, La Jolla, CA (US) farnesoid X receptor for liver and metabolic disorders.” Trends in c - r Molecular Medicine, Jul. 2007. 13(7) 298–309.* (*) Notice: Subj ect to any disclaimer, the term of this Scotti E, Gilardi F. Godio C, Gers E, Krneta J. Mitro N. De Fabiani E. patent is extended or adjusted under 35 Caruso D, and Crestani M. "Bile acids and their signaling pathways: U.S.C. 154(b) by 907 days. eclectic regulators of diverse cellular functions.” Cellular and Molecular Life Sciences, Oct. 2007, 64(19-20), 2477-2491.* (21) Appl. No.: 10/535,043 Laffitte et al., “Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor.” Journal (22) PCT Filed: Nov. 14, 2003 of Biological Chemistry, 275: 10638-10647, 2000. Nicolaou et al., “Natural product-like combinatorial libraries based (86).
    [Show full text]